Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) ...
Too Old to Operate14d
Renal-Limited TMA After Allo-HSCT With Membranous Nephropathy
The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and membranous nephropathy after allogeneic hematopoietic stem cell transplantation ...
Hosted on MSN1mon
Narsoplimab shows promise in reducing mortality for TA-TMA patients
today reported results from sensitivity analyses confirming the effectiveness of its investigational drug narsoplimab in treating thrombotic microangiopathy (TA-TMA) after hematopoietic stem cell ...
Business Wire11d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial
Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Omeros announces results for narsoplimab expanded access program
Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...